Koss-Olinger Consulting’s Arcturus Therapeutics ARCT Stock Holding History

Koss-Olinger Consulting’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,300	Closed	-$293K	–	60
2023 Q4	$293K	Hold	9,300	–	–	0.03%	240
2023 Q3	$238K	Sell	9,300 -4,675	-33%	-$144K	0.04%	228
2023 Q2	$401K	Hold	13,975	–	–	0.05%	154
2023 Q1	$335K	Buy	+13,975	New	+$251K	0.04%	164
2021 Q4	–	Sell	-43,800	Closed	-$2.09M	–	219
2021 Q3	$2.09M	Sell	43,800 -15,000	-26%	-$672K	0.34%	24
2021 Q2	$1.99M	Buy	58,800 +38,800	+194%	+$1.31M	0.3%	37
2021 Q1	$826K	Buy	+20,000	New	+$1.19M	0.14%	91

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Koss-Olinger Consulting's ARCT Position: Q1 2024 in Review

Koss-Olinger Consulting sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 9,300 shares — an estimated $293K sold.

Koss-Olinger Consulting first reported a position in ARCT in Q1 2021 and held it in 7 quarters. The position peaked at $2.09M in Q3 2021. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

Koss-Olinger Consulting reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
Koss-Olinger Consulting sold 9,300 Arcturus Therapeutics shares in Q1 2024, an estimated $293K.
Koss-Olinger Consulting first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 7 quarters.
Koss-Olinger Consulting's Arcturus Therapeutics position peaked at $2.09M in Q3 2021.
179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Koss-Olinger Consulting's 13F filing for Q1 2024, filed 18 Apr 2024.